Cardinal Health (CAH)
(Delayed Data from NYSE)
$102.58 USD
+1.92 (1.91%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $102.37 -0.21 (-0.20%) 5:18 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$102.58 USD
+1.92 (1.91%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $102.37 -0.21 (-0.20%) 5:18 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio
by Zacks Equity Research
Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.
ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40
by Zacks Equity Research
ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.
Here's Why You Should Hold on to Neogen (NEOG) Stock Now
by Zacks Equity Research
Solid progress in long-term growth strategies bodes well for Neogen (NEOG).
Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPUS
Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable
by Zacks Equity Research
Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.
DaVita (DVA) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in its kidney care.
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
DaVita (DVA) Expands Operational Footprint Via New Agreement
by Zacks Equity Research
DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.
Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth
by Zacks Equity Research
With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Stryker (SYK) Completes First Arthroplasty Surgery in Europe
by Zacks Equity Research
Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.
DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval
by Zacks Equity Research
DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.
The Zacks Analyst Blog Highlights The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works
by Zacks Equity Research
The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works are included in this Analyst Blog.
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Investors target stocks that have lately been on a bull run. Stocks like PPC, SUN, CAH and TXT are seeing price strength and have a high chance of carrying the momentum forward.
Haemonetics (HAE) Signs Agreement to Acquire Attune Medical
by Zacks Equity Research
Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.
Best Growth Stocks to Buy for March 6th
by Zacks Equity Research
PAGS, CAH and NVDA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 6, 2023.
3 Top-Ranked Stocks to Buy for Stability
by Derek Lewis
Targeting low-beta stocks can provide a valuable layer of stability for portfolios. After all, defense wins ballgames.
Reasons to Retain Prestige Consumer (PBH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.
CVS Health (CVS) Expands In-Home Diagnostic Care With New Test
by Zacks Equity Research
CVS Health's (CVS) new launch will enable early detection of heart arrhythmia and can help mitigate symptoms and more severe complications.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) focus on R&D raises optimism about the stock.
Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use
by Zacks Equity Research
Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.